Nektar Therapeutics (NKTR): Price and Financial Metrics

Nektar Therapeutics (NKTR): $0.51

0.01 (-1.18%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

B

Add NKTR to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#60 of 345

in industry

NKTR Price/Volume Stats

Current price $0.51 52-week high $3.19
Prev. close $0.52 52-week low $0.41
Day low $0.50 Volume 211,455
Day high $0.53 Avg. volume 4,153,431
50-day MA $0.51 Dividend yield N/A
200-day MA $0.73 Market Cap 97.08M

NKTR Stock Price Chart Interactive Chart >

NKTR POWR Grades

  • NKTR scores best on the Quality dimension, with a Quality rank ahead of 77.49% of US stocks.
  • The strongest trend for NKTR is in Growth, which has been heading down over the past 167 days.
  • NKTR ranks lowest in Momentum; there it ranks in the 6th percentile.

NKTR Stock Summary

  • NKTR's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.91 -- higher than just 11.87% of US-listed equities with positive expected earnings growth.
  • Of note is the ratio of NEKTAR THERAPEUTICS's sales and general administrative expense to its total operating expenses; only 9.91% of US stocks have a lower such ratio.
  • The volatility of NEKTAR THERAPEUTICS's share price is greater than that of 83.71% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to NKTR, based on their financial statements, market capitalization, and price volatility, are ABSI, XPER, AU, FF, and ILMN.
  • Visit NKTR's SEC page to see the company's official filings. To visit the company's web site, go to www.nektar.com.

NKTR Valuation Summary

  • In comparison to the median Healthcare stock, NKTR's price/sales ratio is 71.05% lower, now standing at 1.1.
  • Over the past 243 months, NKTR's EV/EBIT ratio has gone up 16.8.

Below are key valuation metrics over time for NKTR.

Stock Date P/S P/B P/E EV/EBIT
NKTR 2023-11-20 1.1 0.6 -0.3 -0.6
NKTR 2023-11-17 1.0 0.6 -0.3 -0.6
NKTR 2023-11-16 1.1 0.6 -0.3 -0.6
NKTR 2023-11-15 1.1 0.6 -0.3 -0.6
NKTR 2023-11-14 1.1 0.6 -0.3 -0.6
NKTR 2023-11-13 1.0 0.5 -0.3 -0.5

NKTR Growth Metrics

    Its 3 year revenue growth rate is now at -91.29%.
  • The 4 year price growth rate now stands at 9.49%.
  • The 2 year net income to common stockholders growth rate now stands at -6.61%.
NKTR's revenue has moved down $19,576,000 over the prior 33 months.

The table below shows NKTR's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 95.041 -397.842 -454.155
2022-06-30 96.337 -416.091 -524.812
2022-03-31 103.082 -423.999 -491.263
2021-12-31 101.907 -412.66 -523.837
2021-09-30 100.36 -359.756 -495.395
2021-06-30 105.472 -311.295 -474.275

NKTR's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NKTR has a Quality Grade of C, ranking ahead of 63.19% of graded US stocks.
  • NKTR's asset turnover comes in at 0.072 -- ranking 285th of 682 Pharmaceutical Products stocks.
  • CALA, ACOR, and CGEN are the stocks whose asset turnover ratios are most correlated with NKTR.

The table below shows NKTR's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.072 0.779 -0.370
2021-03-31 0.083 0.830 -0.314
2020-12-31 0.094 0.873 -0.301
2020-09-30 0.094 0.871 -0.268
2020-06-30 0.086 0.874 -0.230
2020-03-31 0.068 0.856 -0.223

NKTR Price Target

For more insight on analysts targets of NKTR, see our NKTR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $29.91 Average Broker Recommendation 1.68 (Moderate Buy)

Nektar Therapeutics (NKTR) Company Bio


Nektar Therapeutics is a biopharmaceutical company, developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline includes drug candidates in therapeutic areas comprising oncology, pain, anti-infectives, and immunology.


NKTR Latest News Stream


Event/Time News Detail
Loading, please wait...

NKTR Latest Social Stream


Loading social stream, please wait...

View Full NKTR Social Stream

Latest NKTR News From Around the Web

Below are the latest news stories about NEKTAR THERAPEUTICS that investors may wish to consider to help them evaluate NKTR as an investment opportunity.

Nektar Therapeutics (NASDAQ:NKTR) Q3 2023 Earnings Call Transcript

Nektar Therapeutics (NASDAQ:NKTR) Q3 2023 Earnings Call Transcript November 7, 2023 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.24 EPS, expectations were $-0.18. Operator: Good day and thank you for standing by. Welcome to the Nektar Therapeutics Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please be advised that today’s conference is […]

Yahoo | November 9, 2023

Nektar Therapeutics (NKTR) Incurs Wider-Than-Expected Q3 Loss

Nektar (NKTR) misses third-quarter estimates for the bottom line but beats the same for the top line.

Yahoo | November 8, 2023

Nektar Therapeutics Reports Third Quarter 2023 Financial Results

Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2023.

Yahoo | November 7, 2023

Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2023 on Tuesday, November 7, 2023, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.

Yahoo | October 31, 2023

Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy?

Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | October 26, 2023

Read More 'NKTR' Stories Here

NKTR Price Returns

1-mo -7.27%
3-mo -10.99%
6-mo -15.35%
1-year -82.83%
3-year -97.07%
5-year -98.66%
YTD -77.43%
2022 -83.27%
2021 -20.53%
2020 -21.24%
2019 -34.33%
2018 -44.96%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!